60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock Rating Upgraded by Wall Street Zen

60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by equities researchers at Wall Street Zen to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts have also recently commented on the stock. Ascendiant Capital Markets dropped their price target on shares of 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating for the company in a research note on Friday, November 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright boosted their target price on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $17.60.

60 Degrees Pharmaceuticals Stock Up 1.0%

SXTP stock opened at $1.95 on Friday. 60 Degrees Pharmaceuticals has a twelve month low of $1.36 and a twelve month high of $17.68. The stock has a market capitalization of $2.07 million, a price-to-earnings ratio of -0.14 and a beta of 3.01. The firm’s fifty day simple moving average is $3.12 and its two-hundred day simple moving average is $4.12.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.